Tubulis closed a €308 million (≈$356 million) Series C — one of Europe’s largest biotech rounds this year — to advance its next‑generation antibody‑drug conjugates (ADCs), notably TUB‑040 in ovarian and non‑small cell lung cancer. The funding will expand clinical testing into earlier lines and additional tumor types. Investors backed Tubulis’ integrated ADC platform that designs both antibody and payload components in‑house to aim for higher drug‑to‑antibody ratios and improved therapeutic windows. The cash infusion will accelerate multiple clinical programs and support planned presentations and regulatory interactions at upcoming oncology conferences. The round underscores sustained investor appetite for differentiated oncology modalities and validates the ADC model as private capital flows back into ambitious, clinical‑stage developers.